AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms

BCR-ABL negative myeloproliferative neoplasms (MPNs) consist of essential thrombocythemia, polycythemia vera, and myelofibrosis. The majority of patients harbor the JAK2-activating mutation V617F. JAK2 inhibitors were shown to reduce symptom burden and splenomegaly in MPN patients. However, treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Beitzen-Heineke, Antonia, Berenbrok, Nikolaus, Waizenegger, Jonas, Paesler, Sarina, Gensch, Victoria, Udonta, Florian, Vargas Delgado, Maria Elena, Engelmann, Janik, Hoffmann, Friederike, Schafhausen, Philippe, von Amsberg, Gunhild, Riecken, Kristoffer, Beumer, Niklas, Imbusch, Charles D., Lorens, James, Fischer, Thomas, Pantel, Klaus, Bokemeyer, Carsten, Ben-Batalla, Isabel, Loges, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8357258/
https://www.ncbi.nlm.nih.gov/pubmed/34396051
http://dx.doi.org/10.1097/HS9.0000000000000630